SCHEMBL6096576

SCHEMBL6096576

Cc1nn(-c2ccc(CCN)cc2)c(C)c1-c1cccc(C(N)=O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.49
AR P10275 2/20 0.43
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
MGLL Q99685 1/20 0.41
PDE2A O00408 2/20 0.40
PDE10A Q9Y233 2/20 0.40
PDE4D Q08499 1/20 0.40
PDE3A Q14432 1/20 0.40
PDE5A O76074 1/20 0.39
PDE7A Q13946 1/20 0.39
PDE11A Q9HCR9 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096878 0.90 CYP1A2 (0.46) CYP1A2ARALDH1A1HPGDNPC1
SCHEMBL6096568 0.89 CYP1A2 (0.47) CYP1A2ALDH1A1NPC1TP53MAPT
SCHEMBL6096469 0.81 FAAH (0.53) CYP1A2NPC1RAB9A
SCHEMBL6096828 0.81 CYP1A2 (0.60) CYP1A2ALDH1A1HPGDNPC1TP53
SCHEMBL6100038 0.79 CYP4A11 (0.51) CYP1A2ALDH1A1SMN1; SMN2MGLLOPRM1
SCHEMBL6094749 0.79 CA1 (0.52) MAPT
SCHEMBL6099469 0.79 CA1 (0.43) CYP1A2NPC1RAB9A
SCHEMBL6096951 0.78 CYP1A2 (0.56) CYP1A2ARALDH1A1NPC1RAB9A
SCHEMBL6097546 0.78 CA1 (0.41) CYP1A2NPC1TP53RAB9A
SCHEMBL6099726 0.77 CA2 (0.50) ALDH1A1TP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001917-B2 Pyrazole compounds as anti-inflammatory and analgesic agents WARNER LAMBERT COMPANY LLC (US) 2006-02-21 US disclosed
EP-1495005-A1 PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS Pfizer Japan Inc. (JP) 2005-01-12 EP disclosed
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents HIRANO MISATO (JP) 2004-01-29 US disclosed
WO-2003087061-A1 PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents PTGER1, PTGS1, PTGIR CYP1A2 670/4885AR 110/4885ALDH1A1 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.